RXRX Institutional Ownership
RECURSION PHARMACEUTICALS-A
Latest close $3.20 as of Aug 5, 2026
Institutional Research
Each institution is compared with its own prior filing, then the latest institution-level directions are compared for breadth.
2 accumulating across 2 comparable institutions.
The overall consensus is public. Detailed holder comparisons, breadth history, ownership charts, and filing-specific signal analysis remain part of Investor and Pro research.
Price context
52-week position is market context and does not change the institutional consensus score.
Tracked institutions
Public holder names and filing freshness. Detailed institution-by-institution analysis is locked.
Beneficial ownership filing history
Showing 3 of 10 parsed filing(s) · 7 older require more history access| Holder | Observed / filed | Reported change | Shares | Ownership | Observation | Filing | Latest |
|---|---|---|---|---|---|---|---|
| Vanguard Capital Management CIK0002100119 | Jun 30, 2026 observed Jul 31, 2026 filed · 31d Initial Schedule 13G | Initial Schedule 13G | 26.7M | 12.00% | $3.67 | $3.00 | $3.20 |
| BlackRock CIK0002012383 | Jun 30, 2026 observed Jul 29, 2026 filed · 29d Schedule 13G amendment | Reported accumulation | 44.5M +6.7M | 12.00% 0.00 pts | $3.67 | $2.97 | $3.20 |
| State Street CIK0000093751 | Mar 31, 2026 observed May 12, 2026 filed · 42d Initial Schedule 13G | Initial Schedule 13G | 28.5M +15.6M | 12.00% 0.00 pts | $3.07 | $3.15 | $3.20 |
Related research
Crawlable links to other securities with similar institutional consensus or recent multi-institution accumulation.